Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125429 | 1.00 | KCNH2 (0.45) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| Bromide SCHEMBL14892044 | 0.99 | KCNH2 (0.44) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| Hydrochloric Acid SCHEMBL14890691 | 0.99 | KCNH2 (0.44) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| Hydrochloric Acid SCHEMBL14890692 | 0.99 | KCNH2 (0.44) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| Bromide SCHEMBL14892271 | 0.99 | KCNH2 (0.44) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| SCHEMBL28302568 | 0.92 | CYP3A4 (0.48) | KCNH2CHRM2CHRM1CHRM3HRH1 | |
| SCHEMBL13601296 | 0.90 | OPRM1 (0.44) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| SCHEMBL14128532 | 0.89 | CHRM3 (0.56) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| SCHEMBL11478311 | 0.89 | CHRM3 (0.56) | KCNH2HTR2AHTR2BOPRM1ADRB2 | |
| SCHEMBL11479218 | 0.81 | CHRM2 (0.49) | KCNH2HTR2AHTR2BOPRM1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063369-B | Preparation method of doxepin hydrochloride | 成都瑞尔医药科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-118063369-A | Preparation method of doxepin hydrochloride | 成都瑞尔医药科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20130109854-A1 | Novel Methods for Preparation of (+)-1-ethyl-4-[2-(4-morpholinyl)ethyl)-3,3-diphenyl-2-pyrrolidinone and Salts Thereof | GALLEON PHARMACEUTICALS, INC. | 2013-05-02 | — | — | US | claimed |
| CN-118063369-B | Preparation method of doxepin hydrochloride | 成都瑞尔医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118063369-A | Preparation method of doxepin hydrochloride | 成都瑞尔医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20130109854-A1 | Novel Methods for Preparation of (+)-1-ethyl-4-[2-(4-morpholinyl)ethyl)-3,3-diphenyl-2-pyrrolidinone and Salts Thereof | GALLEON PHARMACEUTICALS, INC. | 2013-05-02 | — | — | US | disclosed |
| WO-2012166909-A1 | COMPOSITIONS AND METHODS FOR TREATING BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120270848-A1 | Novel Compositions and Therapeutic Methods Using Same | GALLEON PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120101073-A1 | Novel Method For Treating Breathing Disorders or Diseases | GALLEON PHARMACEUTICAL, INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120101073-A1 | Novel Method For Treating Breathing Disorders or Diseases | GALLEON PHARMACEUTICAL, INC. | 2012-04-26 | — | — | US | disclosed |
| WO-2012054813-A1 | NOVEL METHODS FOR TREATING BREATHING DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101073-A1 | Novel Method For Treating Breathing Disorders or Diseases | ACER2, ASAH2, PDE12 | KCNH2 1473/4885HTR2A 3319/4885HTR2B 3047/4885 |
| US-20130109854-A1 | Novel Methods for Preparation of (+)-1-ethyl-4-[2-(4-morpholinyl)ethyl)-3,3-diphenyl-2-pyrrolidinone and Salts Thereof | TNNC1, DNPEP, TNNT2 | KCNH2 2946/4885HTR2A 2161/4885HTR2B 2676/4885 |
| US-20120270848-A1 | Novel Compositions and Therapeutic Methods Using Same | OPRM1, OPRK1, OPRD1 | KCNH2 1129/4885HTR2A 666/4885HTR2B 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.